Cargando…
Myeloid ERK5 deficiency suppresses tumor growth by blocking protumor macrophage polarization via STAT3 inhibition
Owing to the prevalence of tumor-associated macrophages (TAMs) in cancer and their unique influence upon disease progression and malignancy, macrophage-targeted interventions have attracted notable attention in cancer immunotherapy. However, tractable targets to reduce TAM activities remain very few...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
National Academy of Sciences
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5866536/ https://www.ncbi.nlm.nih.gov/pubmed/29507229 http://dx.doi.org/10.1073/pnas.1707929115 |
_version_ | 1783308847364964352 |
---|---|
author | Giurisato, Emanuele Xu, Qiuping Lonardi, Silvia Telfer, Brian Russo, Ilaria Pearson, Adam Finegan, Katherine G. Wang, Wenbin Wang, Jinhua Gray, Nathanael S. Vermi, William Xia, Zhengui Tournier, Cathy |
author_facet | Giurisato, Emanuele Xu, Qiuping Lonardi, Silvia Telfer, Brian Russo, Ilaria Pearson, Adam Finegan, Katherine G. Wang, Wenbin Wang, Jinhua Gray, Nathanael S. Vermi, William Xia, Zhengui Tournier, Cathy |
author_sort | Giurisato, Emanuele |
collection | PubMed |
description | Owing to the prevalence of tumor-associated macrophages (TAMs) in cancer and their unique influence upon disease progression and malignancy, macrophage-targeted interventions have attracted notable attention in cancer immunotherapy. However, tractable targets to reduce TAM activities remain very few and far between because the signaling mechanisms underpinning protumor macrophage phenotypes are largely unknown. Here, we have investigated the role of the extracellular-regulated protein kinase 5 (ERK5) as a determinant of macrophage polarity. We report that the growth of carcinoma grafts was halted in myeloid ERK5-deficient mice. Coincidentally, targeting ERK5 in macrophages induced a transcriptional switch in favor of proinflammatory mediators. Further molecular analyses demonstrated that activation of the signal transducer and activator of transcription 3 (STAT3) via Tyr705 phosphorylation was impaired in erk5-deleted TAMs. Our study thus suggests that blocking ERK5 constitutes a treatment strategy to reprogram macrophages toward an antitumor state by inhibiting STAT3-induced gene expression. |
format | Online Article Text |
id | pubmed-5866536 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | National Academy of Sciences |
record_format | MEDLINE/PubMed |
spelling | pubmed-58665362018-03-29 Myeloid ERK5 deficiency suppresses tumor growth by blocking protumor macrophage polarization via STAT3 inhibition Giurisato, Emanuele Xu, Qiuping Lonardi, Silvia Telfer, Brian Russo, Ilaria Pearson, Adam Finegan, Katherine G. Wang, Wenbin Wang, Jinhua Gray, Nathanael S. Vermi, William Xia, Zhengui Tournier, Cathy Proc Natl Acad Sci U S A PNAS Plus Owing to the prevalence of tumor-associated macrophages (TAMs) in cancer and their unique influence upon disease progression and malignancy, macrophage-targeted interventions have attracted notable attention in cancer immunotherapy. However, tractable targets to reduce TAM activities remain very few and far between because the signaling mechanisms underpinning protumor macrophage phenotypes are largely unknown. Here, we have investigated the role of the extracellular-regulated protein kinase 5 (ERK5) as a determinant of macrophage polarity. We report that the growth of carcinoma grafts was halted in myeloid ERK5-deficient mice. Coincidentally, targeting ERK5 in macrophages induced a transcriptional switch in favor of proinflammatory mediators. Further molecular analyses demonstrated that activation of the signal transducer and activator of transcription 3 (STAT3) via Tyr705 phosphorylation was impaired in erk5-deleted TAMs. Our study thus suggests that blocking ERK5 constitutes a treatment strategy to reprogram macrophages toward an antitumor state by inhibiting STAT3-induced gene expression. National Academy of Sciences 2018-03-20 2018-03-05 /pmc/articles/PMC5866536/ /pubmed/29507229 http://dx.doi.org/10.1073/pnas.1707929115 Text en Copyright © 2018 the Author(s). Published by PNAS. https://creativecommons.org/licenses/by-nc-nd/4.0/ This open access article is distributed under Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
spellingShingle | PNAS Plus Giurisato, Emanuele Xu, Qiuping Lonardi, Silvia Telfer, Brian Russo, Ilaria Pearson, Adam Finegan, Katherine G. Wang, Wenbin Wang, Jinhua Gray, Nathanael S. Vermi, William Xia, Zhengui Tournier, Cathy Myeloid ERK5 deficiency suppresses tumor growth by blocking protumor macrophage polarization via STAT3 inhibition |
title | Myeloid ERK5 deficiency suppresses tumor growth by blocking protumor macrophage polarization via STAT3 inhibition |
title_full | Myeloid ERK5 deficiency suppresses tumor growth by blocking protumor macrophage polarization via STAT3 inhibition |
title_fullStr | Myeloid ERK5 deficiency suppresses tumor growth by blocking protumor macrophage polarization via STAT3 inhibition |
title_full_unstemmed | Myeloid ERK5 deficiency suppresses tumor growth by blocking protumor macrophage polarization via STAT3 inhibition |
title_short | Myeloid ERK5 deficiency suppresses tumor growth by blocking protumor macrophage polarization via STAT3 inhibition |
title_sort | myeloid erk5 deficiency suppresses tumor growth by blocking protumor macrophage polarization via stat3 inhibition |
topic | PNAS Plus |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5866536/ https://www.ncbi.nlm.nih.gov/pubmed/29507229 http://dx.doi.org/10.1073/pnas.1707929115 |
work_keys_str_mv | AT giurisatoemanuele myeloiderk5deficiencysuppressestumorgrowthbyblockingprotumormacrophagepolarizationviastat3inhibition AT xuqiuping myeloiderk5deficiencysuppressestumorgrowthbyblockingprotumormacrophagepolarizationviastat3inhibition AT lonardisilvia myeloiderk5deficiencysuppressestumorgrowthbyblockingprotumormacrophagepolarizationviastat3inhibition AT telferbrian myeloiderk5deficiencysuppressestumorgrowthbyblockingprotumormacrophagepolarizationviastat3inhibition AT russoilaria myeloiderk5deficiencysuppressestumorgrowthbyblockingprotumormacrophagepolarizationviastat3inhibition AT pearsonadam myeloiderk5deficiencysuppressestumorgrowthbyblockingprotumormacrophagepolarizationviastat3inhibition AT finegankatherineg myeloiderk5deficiencysuppressestumorgrowthbyblockingprotumormacrophagepolarizationviastat3inhibition AT wangwenbin myeloiderk5deficiencysuppressestumorgrowthbyblockingprotumormacrophagepolarizationviastat3inhibition AT wangjinhua myeloiderk5deficiencysuppressestumorgrowthbyblockingprotumormacrophagepolarizationviastat3inhibition AT graynathanaels myeloiderk5deficiencysuppressestumorgrowthbyblockingprotumormacrophagepolarizationviastat3inhibition AT vermiwilliam myeloiderk5deficiencysuppressestumorgrowthbyblockingprotumormacrophagepolarizationviastat3inhibition AT xiazhengui myeloiderk5deficiencysuppressestumorgrowthbyblockingprotumormacrophagepolarizationviastat3inhibition AT tourniercathy myeloiderk5deficiencysuppressestumorgrowthbyblockingprotumormacrophagepolarizationviastat3inhibition |